e7090
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 10, 2014 (NCT02275910)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- e7090
- e7090
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04962867 | Phase 2 | Jun 15, 2021 | Eisai, National Cancer Center, Japan |
| NCT04572295 | Phase 1 | Oct 9, 2020 | Eisai |
| NCT04493255 | Phase 1 | Sep 30, 2020 | Eisai |
| NCT04565574 | Phase 1 | Sep 24, 2020 | Eisai |
| NCT04271488 | Phase 1 | Feb 19, 2020 | Eisai |
| NCT04238715 | Phase 2 | Jan 27, 2020 | Eisai |
| NCT02275910 | Phase 1 | Nov 10, 2014 | Eisai |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 7 | 6 | 2 | 2014 |
| National Cancer Center, Japan | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1